Colorectal Cancer Treatments
Find Colorectal Cancer Treatments
Xeloda
What is Xeloda (Capecitabine)?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor...
Summary: This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolera...
Summary: This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery. The study will evaluate whether perioperative treatment with Retlirafusp alfa, famitinib malate, and hepatic arterial infusion chemotherapy using gemcitabine and oxaliplatin (HAIC-GEMO...
Related Latest Advances
Brand Information
• Test patients for genetic variants of
Increased risk of bleeding with concomitant use of Vitamin K antagonists
• Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with oral vitamin K antagonists, such as warfarin [see
• Clinically significant increases in prothrombin time (PT) and international normalized ratio (INR) have been reported in patients who were on stable doses of a vitamin K antagonist at the time XELODA was introduced. These events occurred in patients with and without liver metastases.
• Monitor INR more frequently and adjust the dose of the vitamin K antagonist as appropriate [see
- 150 mg: biconvex, oblong, light-peach colored, with "XELODA" on one side and "150" on the other
- 500 mg: biconvex, oblong, peach colored, with "XELODA on one side and "500" on the other
- Cardiotoxicity
- Diarrhea
- Dehydration
- Renal Toxicity
- Serious Skin Toxicities
- Palmar-Plantar Erythrodysesthesia Syndrome
- Myelosuppression
- Hyperbilirubinemia



- 150 mg, biconvex, oblong, film-coated, light peach tablets with "XELODA" on one side and "150" on the other; available in bottles of 60 tablets (NDC 61269-470-60), individually packaged in a carton.
- 500 mg, biconvex, oblong, film-coated, peach tablets with "XELODA" on one side and "500" on the other; available in bottles of 120 tablets (NDC 61269-475-12), individually packaged in a carton.




